ASCO 2023 | Phase II study of vibecotamab in MRD+ AML and MDS & CMML after HMA failure
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a Phase II study investigating the CD3-CD123 bispecific antibody vibecotamab in patients with measurable residual disease (MRD)-positive acute myeloid leukemia, myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) with low bone marrow blasts (NCT05285813).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Pfizer: Consultancy; Stemline Therapeutics: Research Funding; AstraZeneca: Consultancy; Amgen: Consultancy, Honoraria.
